Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 Price-to-Operating-Cash-Flow is 7.30 as of Aug. 04, 2026, which is 4% below its 10-year median of 7.58. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 296 Biotechnology companies, Puma Biotechnology ranks better than 87.5% on this metric.
As of today (2026-08-04), Puma Biotechnology's share price is $7.69.
Puma Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.05. Hence, Puma Biotechnology's Price-to-Operating-Cash-Flow Ratio for today is 7.30.
The historical rank and industry rank for Puma Biotechnology's Price-to-Operating-Cash-Flow or its related term are showing as below:
PBYI'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.24 Med: 7.58 Max: 875.71
Current: 7.29
During the past 13 years, Puma Biotechnology's highest Price-to-Operating-Cash-Flow Ratio was 875.71. The lowest was 3.24. And the median was 7.58.
PBYI's Price-to-Operating-Cash-Flow is ranked better than 87.5% of 296
companies
in the Biotechnology industry
Industry Median: 22.425
vs PBYI: 7.29
Puma Biotechnology's Cash Flow from Operations per share for the
three
months ended in Mar. 2026 was $0.30.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.05.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Puma Biotechnology was 66.40% per year.
During the past 13 years, Puma Biotechnology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 205.10% per year. The lowest was -1142.50% per year. And the median was -31.90% per year.
Puma Biotechnology Price-to-Operating-Cash-Flow Related Terms
Puma Biotechnology Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: Price-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, Puma Biotechnology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Price-to-Operating-Cash-Flow falls into.
Puma Biotechnology's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
7.69
/
1.053
=
7.30
Puma Biotechnology's Share Price of today is $7.69. Puma Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 7.30 mean?
Puma Biotechnology (PBYI) has a Price-to-Operating-Cash-Flow of 7.30 as of Aug. 04, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Puma Biotechnology and its competitors. This is near median its historical median of 7.58. Over the past decade, Puma Biotechnology's Price-to-Operating-Cash-Flow has ranged from 3.24 to 875.71. According to the industry distribution chart, Puma Biotechnology ranks #37 out of 296 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Puma Biotechnology's Price-to-Operating-Cash-Flow too high?
Puma Biotechnology's current Price-to-Operating-Cash-Flow of 7.30 is near median its 10-year median of 7.58. Over the past 10 years, this metric has ranged from a low of 3.24 to a high of 875.71. The Biotechnology industry median Price-to-Operating-Cash-Flow is 22.43. Puma Biotechnology's value of 7.30 is 67.4% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #37 out of 296 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Price-to-Operating-Cash-Flow compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #37 out of 296 companies for Price-to-Operating-Cash-Flow. This places Puma Biotechnology in the top 13% of its industry — outperforming the majority of peers. The industry median Price-to-Operating-Cash-Flow is 22.43. Puma Biotechnology's value of 7.30 is 67.4% below this benchmark. Historically, Puma Biotechnology's own Price-to-Operating-Cash-Flow has ranged from 3.24 to 875.71 over the past decade. While the company's 10-year median is 7.58 vs. the industry median of 22.43, Puma Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Biotechnology company?
The median Price-to-Operating-Cash-Flow among Biotechnology companies is 22.43, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Price-to-Operating-Cash-Flow of 7.30 is 67.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median Price-to-Operating-Cash-Flow is 22.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Price-to-Operating-Cash-Flow is 7.30, which is near median its own 10-year median of 7.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Price-to-Operating-Cash-Flow is 7.30, which is near median its 10-year median of 7.58 and 67.4% below the Biotechnology industry median of 22.43. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Price-to-Operating-Cash-Flow is 7.30 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Price-to-Operating-Cash-Flow: 7.30 (near median its 10-year median of 7.58)
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
Industry Position: 67.4% below the Biotechnology median (#37 of 296)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
